A Multi-center, Placebo-controlled, randomized pilot study of the effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and Hepatocellular Carcinoma Treated with Ablative Therapy and/or Transarterial Chemoembolization
Disease/Condition: Hepatocellular Carcinoma
Principal Investigator: Guadalupe Garcia-Tsao |
A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib
Disease/Condition: Hepatocellular Carcinoma | Liver Cancer
Principal Investigator: Stacey M Stein |
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Tumor Malignancies
Disease/Condition: Advanced Solid Cancers
Principal Investigator: Howard S Hochster |
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Disease/Condition: Advanced Malignancies | Anaplastic Large Cell Lymphoma | Carcinoma, Non-Small-Cell Lung | Diffuse Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors
Principal Investigator: Scott Nicholas Gettinger |
A Phase 2 Biomarker Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Disease/Condition: Smoldering Myeloma
Principal Investigator: Madhav V. Dhodapkar |
A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Disease/Condition: Recurrent Ovarian Cancer
Principal Investigator: Thomas Rutherford |
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma (CA204006)
Disease/Condition: Multiple Myeloma
Principal Investigator: Dhodapkar, Madhav |
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Disease/Condition: Advanced Solid Tumors, | Breast Cancer, | Cowden Syndrome
Principal Investigator: Maysa Abu-Khalaf, M.D. |
A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Breast Cancer (ER, PR, and HER2 negative) | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Melanoma | Non-Small Cell Lung Cancer (NSCLC) | Ovarian Cancer | Prostate Cancer
Principal Investigator: Roy Herbst |
A Phase Ib, Open-Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux) in Patients with Non-Small Cell Lung Cancer with Progression Following Prior Erlotinib (Tarceva) or Gefitinib (Iressa)
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Scott Nicholas Gettinger |
A Phase II, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Scott Nicholas Gettinger |
A Phase II, Multi-Center, Double-Blind, placebo controlled, Randomized Study of Ombrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treated with Carboplatin/Paclitaxel
Disease/Condition: Recurrent Ovarian Cancer
Principal Investigator: Thomas Rutherford |
A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (ECOG 1208)
Disease/Condition: Liver Cancer
Principal Investigator: Stacey M Stein |
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-cell Lymphoma Patients
Disease/Condition: Anaplastic Large Cell Lymphoma (ALCL) | Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral | other transformed T-cell lymphomas
Principal Investigator: Francine M Foss |
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients using ColoPrint
Disease/Condition: Colon Cancer
Principal Investigator: Vikram Reddy |
A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Disease/Condition: Breast Cancer
Principal Investigator: Anees B. Chagpar |
A Randomized, 3 Arm, Multicentre, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined with Pertuzumab or T-DM1 Combined with Pertuzumab-placebo (blinded for pertuzumab), Versus the Combination of Trastuzumab plus Taxane, as First Line Treatment in HER2-Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer (MBC)
Disease/Condition: Breast Cancer
Principal Investigator: Maysa Mahmoud Abu-Khalaf |
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
Disease/Condition: Breast Cancer
Principal Investigator: Maysa Mahmoud Abu-Khalaf |
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Roy Herbst |
A Single-arm, Multicenter, Proof-of-Concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonates
Disease/Condition: Hypercalcemia
Principal Investigator: Karl L. Insogna |
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Disease/Condition: Advanced Malignancies
Principal Investigator: Dhodapkar, Madhav V. |
Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery
Disease/Condition: Basal Cell Carcinoma | Squamous Cell Carcinoma
Principal Investigator: David Leffell, MD |
ACRIN 6690: A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Disease/Condition: Liver Cancer
Principal Investigator: Jeffrey C. Weinreb |
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Deach-1 (PD-1) Antibody (BMS-936558) in Subjects with Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Disease/Condition: Renal Cell Carcinoma | Renal Cell Carcinoma (RCC)
Principal Investigator: Mario Sznol, MD |
An Intervention to Improve Outcomes in Patients With Advanced Cancer
Disease/Condition: Cancer
Principal Investigator: Ruth McCorkle, RN, PhD |
An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thromboythemia Myelofibrosis and Post Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50x109 /L to 100 x 109/L
Disease/Condition: Post Essential Thromboythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis | Primary Myelofibrosis
Principal Investigator: Nikolai Alexandrovich Podoltsev |
An Open-Label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate Toxicity
Disease/Condition: Cancer
Principal Investigator: Peter Marks |
An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine (NO25530B)
Disease/Condition: Metastatic Thyroid Cancer | Unresectable Papillary Thyroid Cancer
Principal Investigator: Julie Sosa |
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Disease/Condition: Prostate Cancer
Principal Investigator: Hari Anant Deshpande |
Assessment Tool for Older Patients With Cancer
Disease/Condition: Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment | Unspecified Adult Solid Tumor, Protocol Specific
Principal Investigator: Gross, Cary P |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Disease/Condition: Neuroblastoma
Principal Investigator: Kupfer, Gary |
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Disease/Condition: Leukemia | Lymphoma
Principal Investigator: Gary Kupfer |
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Disease/Condition: Cognitive/Functional Effects | Leukemia | Long-term Effects Secondary to Cancer Therapy in Children | Neurotoxicity | Psychosocial Effects of Cancer and Its Treatment
Principal Investigator: Gary Kupfer |
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Disease/Condition: Lung Cancer
Principal Investigator: Roy Herbst |
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Disease/Condition: Endometrial Cancer
Principal Investigator: Masoud Azodi |
Cardiovascular Risk Assessment in Women with Early Breast Cancer
Disease/Condition: Breast Cancer
Principal Investigator: Jessica Marie Coviello |
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Disease/Condition: Fungal Infection | Leukemia | Neutropenia
Principal Investigator: Nina Kadan-Lottick |
Cetuximab and Radiation Therapy in Head and Neck Cancer
Disease/Condition: Head and Neck Cancer
Principal Investigator: Roy Decker |
Characterization of Tumor Cells in the Arterial and Venous Circulations of Non Small Cell Lung Cancer Patients
Disease/Condition: Non Small Cell Lung Cancer
|
Characterization of Tumor Cells in the Arterial and Venous Circulations of Non Small Cell Lung Cancer Patients
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Daniel J. Boffa |
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Disease/Condition: Brain and Central Nervous System Tumors
Principal Investigator: Gary Kupfer |
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Disease/Condition: Lymphoma
Principal Investigator: Dennis L. Cooper |
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Disease/Condition: Fallopian Tube Cancer | Ovarian Cancer | Primary Peritoneal Cavity Cancer
Principal Investigator: Thomas J. Rutherford |
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Disease/Condition: Head and Neck Cancer
Principal Investigator: Hari Anant Deshpande |
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Disease/Condition: Lung Cancer
Principal Investigator: Scott Nicholas Gettinger |
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Disease/Condition: Chordoma | Desmoid Tumor | Sarcoma
Principal Investigator: Gary Kupfer |
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Disease/Condition: Rhabdomyosarcoma
Principal Investigator: Gary Kupfer |
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Disease/Condition: Brain and Central Nervous System Tumors | Kidney Cancer | Sarcoma
Principal Investigator: Gary Kupfer |
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
Disease/Condition: Liver Cancer
Principal Investigator: Nina Kadan-Lottick |
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Disease/Condition: Leukemia | Lymphoma
Principal Investigator: Gary Kupfer |
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor
Disease/Condition: Kidney Cancer | Metastatic Cancer
Principal Investigator: Kupfer, Gary |
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Disease/Condition: Sarcoma
Principal Investigator: Gary Kupfer |
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
Disease/Condition: Lung Cancer
Principal Investigator: Daniel J. Boffa |
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Disease/Condition: Brain and Central Nervous System Tumors
Principal Investigator: Gary Kupfer |
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Disease/Condition: Multiple Myeloma
Principal Investigator: Madhav Dhodapkar, M.D. |
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (UNDER CFR 312.34)
Disease/Condition: Hepatic Veno-Occlusive Disease
Principal Investigator: Stuart Evan Seropian |
Delivery of a Survivorship Care Plan to Breast Cancer Patients, a Feasibility Study
Disease/Condition: Breast Cancer
Principal Investigator: Tara Sanft |
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Disease/Condition: Malignant Melanoma
Principal Investigator: Mario Sznol |
Epidemiology and Genetics of Early Onset Basal Cell Carcinoma
Disease/Condition: Basal Cell Carcinoma
Principal Investigator: Susan T Mayne |
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Disease/Condition: Non-small Cell Lung Cancer
Principal Investigator: Scott Gettinger, MD |
Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease
Disease/Condition: Paget's Disease of the Vulva
Principal Investigator: Thomas J. Rutherford, MD, PhD |
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Disease/Condition: Gastric Cancer | Gastroesophageal Cancer
Principal Investigator: Lacy, Jill |
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Disease/Condition: Metastatic Pancreatic Adenocarcinoma
Principal Investigator: Howard S. Hochster, MD |
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Disease/Condition: Bladder Cancer | Prostate Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
Principal Investigator: Hari Anant Deshpande |
GOG 273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal of Fallopian Tube Cancer –Observational study
Disease/Condition: ovarian, primary peritonial, fallopian tube cancer
Principal Investigator: Thomas Rutherford |
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Disease/Condition: Advanced Breast Cancer
Principal Investigator: Abu-Khalaf, Maysa Mahmoud |
Her2, c-kit EGFR and akt1 Expression in Carcinosarcomas of Female Genital Tract: Prognostic Factors or Potential Markers for Targeted Therapies
Disease/Condition: Gynecological Cancers
Principal Investigator: Ozlen Saglam |
Hormones and Physical Exercise Study
Disease/Condition: Cancer
Principal Investigator: Melinda Liggett Irwin |
Imaging the Effects of R-CHOP and other Anthracycline containing Chemotherapy on Cognitive Function in Patients with high-grade lymphoma
Disease/Condition: Lymphoma
Principal Investigator: Herta H Chao |
Immune Function in T-Cell Lymphoma
Disease/Condition: Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral
Principal Investigator: Francine M Foss |
Immunology and Pathobiology of Plasma Cell Disorders
Disease/Condition: Plasma cell disorder
Principal Investigator: Madhav V. Dhodapkar |
Impact of Exercise on Ovarian Cancer Prognosis
Disease/Condition: Ovarian Cancer
Principal Investigator: Melinda Liggett Irwin |
In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors
Disease/Condition: Pancreatic Cysts
Principal Investigator: Harry Aslanian, MD |
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
Disease/Condition: Melanoma (Skin)
Principal Investigator: Harriet Kluger |
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Disease/Condition: Colorectal Cancer
Principal Investigator: Howard S Hochster |
Longitudinal Assessment and Functional Outcomes in Patients with Hematologic Malignancies and Related Disorders
Disease/Condition: Hematologic Malignancies
Principal Investigator: Stephanie Halene |
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Disease/Condition: Brain and Central Nervous System Tumors | Chronic Myeloproliferative Disorders | Leukemia | Long-term Effects Secondary to Cancer Therapy in Children | Lymphoma | Lymphoproliferative Disorder | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasms | Precancerous Condition | Unspecified Childhood Solid Tumor, Protocol Specific
Principal Investigator: Gary Kupfer |
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Disease/Condition: Cutaneous Lymphoma
Principal Investigator: Lynn Deyo Wilson |
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Disease/Condition: Leukemia
Principal Investigator: Kupfer, Gary |
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Disease/Condition: Brain and Central Nervous System Tumors
Principal Investigator: Gary Kupfer |
Maintenance Therapy with Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Disease/Condition: Chronic Lymphocytic Leukemia
Principal Investigator: Dennis Cooper, MD |
Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma
Disease/Condition: Breast Neoplasms
Principal Investigator: Weidhaas, Joanne Barnes |
Molecular Analysis of Invasive Micropapillary Breast Cancer
Disease/Condition: Breast Cancer
Principal Investigator: Gina G Chung |
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Disease/Condition: Breast Cancer
Principal Investigator: Abu-Khalaf, Maysa Mahmoud |
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
Disease/Condition: Brain and Central Nervous System Tumors | Chemotherapeutic Agent Toxicity | Cognitive/Functional Effects | Neurotoxicity | Psychosocial Effects of Cancer and Its Treatment | Radiation Toxicity | Therapy-related Toxicity
Principal Investigator: Gary Kupfer |
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Disease/Condition: Brain and Central Nervous System Tumors
Principal Investigator: Jonathan P. S. Knisely |
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Disease/Condition: Colorectal Cancer
Principal Investigator: Howard S Hochster |
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer
Disease/Condition: Ovarian Cancer | Sarcoma
Principal Investigator: Dan-Arin Silasi |
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
Disease/Condition: Endometrial Cancer | Fatigue | Neurotoxicity
Principal Investigator: Rutherford, Thomas J. |
Phase II Study of FOLFIRINOX for Advanced Pancreatic Cancer
Disease/Condition: Advanced Pancreatic Cancer | Metastatic Pancreatic Cancer | Pancreatic Cancer
Principal Investigator: Jill Lacy, MD |
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920) (CIRB)
Disease/Condition: Head and Neck Cancer
Principal Investigator: Daniel Morgensztern |
Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered in a 72-Hour Continuous IV Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine.
Disease/Condition: Myelodysplastic Syndromes
Principal Investigator: Nikolai Alexandrovich Podoltsev |
Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma
Disease/Condition: Peripheral T-cell Lymphoma
Principal Investigator: Francine M Foss |
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Disease/Condition: Breast Cancer
Principal Investigator: Weidhaas, Joanne Barnes |
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Disease/Condition: Head and Neck Cancer
Principal Investigator: Daniel Morgensztern |
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Disease/Condition: Adenocarcinoma of the Gastroesophageal Junction | Esophageal Cancer
Principal Investigator: Bryan William Chang |
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Disease/Condition: Chronic Myelomonocytic Leukemia | MDS | Myelodysplastic Syndromes | RAEB
Principal Investigator: Nikolai Podoltsev, MD, PhD |
Randomized, double-blind, Phase II Study of FOLFOX/Bevacizumab with MetMAb versus Placebo as First-Line Treatment for Patients with Metastatic Colorectal Cancer
Disease/Condition: Colorectal Cancer
Principal Investigator: Howard S Hochster |
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Disease/Condition: Leukemia
Principal Investigator: Gary Kupfer |
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Disease/Condition: Leukemia
Principal Investigator: Gary Kupfer |
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Disease/Condition: Malignant Melanoma | Melanoma
Principal Investigator: Mario Sznol, MD |
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Disease/Condition: Graft Versus Host Disease | Leukemia | Myelodysplastic Syndromes
Principal Investigator: Warren Shlomchik, MD |
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
Disease/Condition: Stem Cell Transplantation
Principal Investigator: Seropian, Stuart Evan |
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Disease/Condition: Liver Cancer
Principal Investigator: Stacey M Stein |
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Disease/Condition: Ovarian Neoplasms
Principal Investigator: Thomas Rutherford |
Study of Blood Samples From Newborns With Down Syndrome
Disease/Condition: Down Syndrome | Leukemia
Principal Investigator: Nina Kadan-Lottick |
Study of Kidney Tumors in Young Patients
Disease/Condition: Kidney Cancer | Nonneoplastic Condition
Principal Investigator: Gary Kupfer |
Study of Late-Occurring Complications in Childhood Cancer Survivors
Disease/Condition: Cancer
Principal Investigator: Kupfer, Gary |
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Disease/Condition: Breast Cancer
Principal Investigator: Erin Wysong Hofstatter |
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Disease/Condition: Breast Cancer
Principal Investigator: Lyndsay N Harris |
Testing the Feasibility of a Nurse Patient Navigation Intervention in Lung Cancer
Disease/Condition: Lung Cancer
Principal Investigator: Ruth McCorkle |
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Disease/Condition: Kidney Cancer
Principal Investigator: Kupfer, Gary |
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Disease/Condition: Sarcoma
Principal Investigator: Nina Kadan-Lottick |
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Disease/Condition: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Roy Decker, M.D., Ph.D. |
Women With Cancer: An Exercise Study to Promote Health
Disease/Condition: Bone Loss | Cancer
Principal Investigator: M. Tish Knobf, PhD |
Women's Experience with Triple Negative Breast Cancer
Disease/Condition: Breast Cancer
Principal Investigator: Yasemin Turkman |
